29415-97-2

Usage

Uses

1. Used in Pharmaceutical Industry:
Methyl 3-bromo-4-hydroxybenzoate is used as a reactant for the preparation of selective inhibitors. Its unique structure allows it to be a key component in the synthesis of compounds with specific biological activities, making it valuable in the development of new drugs and therapies.
2. Used in Chemical Synthesis:
In the field of chemical synthesis, Methyl 3-bromo-4-hydroxybenzoate serves as a crucial intermediate in the production of various organic compounds. For instance, it is used in the unsymmetrical Ullman reaction between methyl 5-bromovanillate and itself to yield three possible dicarbomethoxy-dibenzo-p-dioxins. These compounds can be separated through repeated chromatography over silica gel, showcasing the versatility of Methyl 3-bromo-4-hydroxybenzoate in chemical reactions.
3. Used in the Preparation of Bifunctional Monomers:
Methyl 3-bromo-4-hydroxybenzoate is also utilized in the synthesis of phosphorusand bromine-containing bifunctional monomers. These monomers are prepared from bis(chloromethyl)methylphosphine oxide and the sodium salt of Methyl 3-bromo-4-hydroxybenzoate. The resulting bifunctional monomers have potential applications in the development of new materials and compounds with specific properties, further expanding the utility of Methyl 3-bromo-4-hydroxybenzoate in the chemical industry.

InChI:InChI=1/C8H7BrO3/c1-12-8(11)5-2-3-7(10)6(9)4-5/h2-4,10H,1H3

Upstream product

• 67-56-1 methanol 
• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 66548-21-8 di(methyl)tert-butyl(methoxy)silane 
• 123-08-0 4-hydroxy-benzaldehyde 
• 99-96-7 4-hydroxy-benzoic acid 
• 67201-23-4 methyl 2-trimethylsilyl-4-trimethylsilyloxycyclohex-3-enecarboxylate 

Downstream Products

• 35450-37-4 methyl 3-bromo-4-methoxybenzoate 
• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 
• 886643-00-1 4-allyloxy-3-bromo-benzoic acid 
• 91802-15-2 3-Bromo-4-(2-dimethylamino-ethoxy)-benzoic acid methyl ester 
• 122289-47-8 methyl 3-bromo-4-<<(S)-1-methylheptyl>oxy>benzoate 
• 122289-46-7 methyl-3-bromo-4-(dodecyloxy)benzoate 
• 149817-68-5 methyl 4-acetoxy-3-bromobenzoate 
• 672922-57-5 3-bromo-4-methoxymethoxybenzoic acid methyl ester 
• 325147-52-2 2-(2-bromo-4-carboxylic acid methyl ester phenoxy)-1-tert-butyldimethylsiloxyethane 
• 162269-91-2 (3-bromo-4-methoxymethoxy-phenyl)-methanol 
• 672922-58-6 2-(3-bromo-4-methoxymethoxy-benzyloxy)-tetrahydro-pyran 
• 672922-61-1 4-Methoxymethoxy-3-[(E)-3-methyl-5-((4aS,8aS)-2,5,5,8a-tetramethyl-3,4,4a,5,6,7,8,8a-octahydro-naphthalen-1-yl)-pent-2-enyl]-benzaldehyde 
• 672922-60-0 {4-Methoxymethoxy-3-[(E)-3-methyl-5-((4aS,8aS)-2,5,5,8a-tetramethyl-3,4,4a,5,6,7,8,8a-octahydro-naphthalen-1-yl)-pent-2-enyl]-phenyl}-methanol 
• 35354-74-6 Honokiol 

Relevant academic research and scientific papers

IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE

Provided is an iridium complex compound represented by formula (1) below. [Ir is an iridium atom. C1 to C6 are carbon atoms. N1 and N2 are nitrogen atoms. R1 to R4 are each a hydrogen atom

Single-Step Dual Functionalization: One-Pot Bromination-Cross-Dehydrogenative Esterification of Hydroxy Benzaldehydes with CCl 3 Br - A Comparison with Selectfluor

Bromination of phenolic compounds without directly using molecular bromine possesses much importance. In this article an Ir III /CCl 3 Br-assisted single-step double functionalization of hydroxy benzaldehydes is reported. It involves simultaneous esterification of the aldehyde group and bromination of the aryl ring of phenolic aldehydes in one-pot. The reaction proceeds under mild conditions in the presence of 445 nm blue LED light to obtain highly functionalized bromo hydroxy benzoates in moderate to good yields. In comparison, Selectfluor as an oxidant gives only non-bromo phenolic esters.

CARBOXY SUBSTITUTED (HETERO) AROMATIC RING DERIVATIVES AND PREPARATION METHOD AND USES THEREOF

Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF

The present disclosure provides new procedures and intermediates for the preparation of Sofosbuvir.

TRICYCLIC COMPOUND AND USE THEREOF

The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereof. The compound effectively controls GPR40, and thus, can be effectively used for the prophylaxis or treatment of diseases associated with GPR40, for example, diabetes and many other diseases.

Discovery of AM-1638: A potent and orally bioavailable GPR40/FFA1 full agonist

GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels. A potent, orally bioavailable small molecule GPR40 agonist

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors

New 7,8-dihydro-1,6-naphthyridin-5(6H)-one derivatives derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

PYRROLIDINE GPR40 MODULATORS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.